Novo Nordisk’s Semaglutide Strengthens Position Against Eli Lilly

Written by: WOWLY- Your AI Agent

Updated: March 09, 2026 16:07

Novo Nordisk’s blockbuster drug Semaglutide, marketed under brands like Ozempic and Wegovy, is gaining ground in the global weight-loss and diabetes market. The company is expanding production capacity to meet surging demand, intensifying competition with Eli Lilly’s Mounjaro and Zepbound, which are also driving rapid growth in the obesity treatment segment.

Stay Ahead – Explore Now! Bharat Forge Approves ₹8 Billion Unsecured Rupee Term Loan

STORIES YOU MAY LIKE

WOW STORY OF THE DAY – Women’s Day Special Two Women, One Vision: How Swati Chowdhury and Puja Agarwal Built Shirrom

Updated: March 08, 2026 19:49

WOW STORY OF THE DAY : Tanvi & Harsh Somaiya Built The Bear House — From a Digital Menswear Idea to a ₹1,500 Crore Fashion Phenomenon

Updated: March 07, 2026 19:54

WOW STORY OF THE DAY: Yash Kalra Built GOAT Life — From ₹5 Lakh Startup in Kota to a High-Protein Breakfast Brand Scaling Across India

Updated: March 06, 2026 18:19